시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 가족성 선종성 용종증 치료 시장 보고서(2025년)
Familial Adenomatous Polyposis Treatment Global Market Report 2025
상품코드 : 1750995
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

가족성 선종성 용종증 치료 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 헬스케어 인프라의 확대, 유전자 검사와 상담 수요 증가 등의 요인에 의한 것입니다. 이 기간의 주요 동향에는 치료법의 진보, 유전자 연구의 발전, 혁신적 기술의 사용, 집학적 치료 모델의 통합, 맞춤형 의료 어프로치의 인기 증가 등이 있습니다.

헬스케어 지출 증가는 가족성 선종성 용종증 치료 시장 확대를 촉진할 것으로 예측됩니다. 건강 관리 지출 증가는 인구의 고령화와 의료 기술의 진보에 의한 곳이 커집니다. 헬스케어 지출의 급증은 FAP 치료의 연구개발을 촉진하고 조기 발견, 질병 관리, 환자의 결과를 향상시키는 유전자 검사, 표적 치료, 최소 침습 수술 등의 기술 혁신을 가져옵니다. 예를 들어, 2024년 12월 미국 연방 기관인 메디케어 및 메디케이드 서비스 센터는 미국의 메디케어 지출이 8.1% 증가하여 1조 2,298억 달러에 달했으며, 이는 전체 국민 건강 지출(NHE)의 21%를 차지한다고 보고했습니다.

최소 침습 수술 증가는 가족성 선종성 용종증 치료 시장 성장을 가속화할 것으로 예측됩니다. 그리고 보다 적은 위험으로 상태를 진단 또는 치료하는 의료 기술을 포함합니다. 최소 침습 수술의 채용이 증가하고 있는 배경에는 의료 기술의 진보나, 보다 빠른 회복을 요구하는 환자 수요 증가가 있습니다. 보다 작은 절개에 의한 수술이 가능해져 합병증의 감소나 입원기간의 단축이 도모되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Familial adenomatous polyposis (FAP) treatment involves both medical and surgical methods to manage this genetic condition, which is characterized by the development of numerous precancerous polyps in the colon and rectum. The primary goal of treatment is to prevent the onset of colorectal cancer, which almost certainly develops if left untreated.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main treatment products for familial adenomatous polyposis include icosapent, eflornithine hydrochloride, aspirin, cetuximab oral formulation (ceq)-508, and others. Icosapent is a purified derivative of eicosapentaenoic acid (EPA), primarily used to lower triglyceride levels. It is used in the treatment of attenuated FAP, familial adenomatous polyposis, Gardner syndrome, and Turcot syndrome. Icosapent is effective in managing symptoms such as bloody stool, unexplained diarrhea, abdominal cramps, bloating, weight loss, lethargy, and vomiting. It is also used for colorectal cancer prevention, genetic counseling, and surgical interventions by various end-users, including clinics, hospitals, diagnostic centers, home healthcare services, and others.

The familial adenomatous polyposis treatment market research report is one of a series of new reports from The Business Research Company that provides familial adenomatous polyposis treatment market statistics, including familial adenomatous polyposis treatment industry global market size, regional shares, competitors with a familial adenomatous polyposis treatment market share, detailed familial adenomatous polyposis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the familial adenomatous polyposis treatment industry. This familial adenomatous polyposis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The familial adenomatous polyposis (FAP) treatment market size has grown rapidly in recent years. It will grow from $1.34 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of familial adenomatous polyposis, excessive tobacco consumption, a rising incidence of genetic disorders, greater healthcare awareness and legislative changes, and the growing prevalence of sedentary lifestyles.

The familial adenomatous polyposis (FAP) treatment market size is expected to see rapid growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth projected for the forecast period can be attributed to factors such as the expanding use of gene therapy, rising demand for effective treatment options, growing awareness of genetic diseases, the expansion of healthcare infrastructure, and increasing demand for genetic testing and counseling. Key trends during this period include advancements in treatment methods, developments in genetic research, the use of innovative techniques, the integration of multidisciplinary care models, and the rising popularity of personalized medicine approaches.

The growing healthcare expenditure is expected to drive the expansion of the familial adenomatous polyposis (FAP) treatment market. Healthcare spending refers to the total costs associated with medical services, treatments, pharmaceuticals, and health-related infrastructure, which are incurred by individuals, governments, and private entities to maintain and improve health outcomes. This rise in healthcare spending is largely due to an aging population and ongoing advancements in medical technology. As life expectancy increases, there is a greater need for long-term care, chronic disease management, and frequent medical interventions, leading to higher healthcare costs. The surge in healthcare spending fosters research and development in FAP treatment, resulting in innovations such as genetic testing, targeted therapies, and minimally invasive procedures that enhance early detection, disease management, and patient outcomes. For example, in December 2024, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that Medicare spending in the US rose by 8.1%, reaching $1,029.8 billion, which accounted for 21% of total national health expenditures (NHE). Thus, the increase in healthcare spending is driving the growth of the FAP treatment market.

The rise in minimally invasive procedures is expected to accelerate the growth of the familial adenomatous polyposis (FAP) treatment market. Minimally invasive procedures involve medical techniques that use smaller incisions, specialized instruments, or imaging guidance to diagnose or treat conditions with less trauma, quicker recovery times, and reduced risks compared to traditional surgery. The growing adoption of minimally invasive procedures is driven by advances in medical technology and increasing patient demand for faster recovery. Innovations in surgical techniques, robotics, and imaging technologies have enabled procedures with smaller incisions, reducing complications and shortening hospital stays. These procedures enhance polyp removal and surveillance in FAP treatment by enabling early detection, precise excision, and fewer complications, which help delay disease progression and reduce the need for extensive surgeries. For instance, in 2023, the American Society of Plastic Surgeons reported a 7% year-over-year growth in minimally invasive procedures in the USA. Consequently, the rise of minimally invasive procedures is contributing to the growth of the FAP treatment market.

Major companies in the familial adenomatous polyposis (FAP) treatment market are making significant strides in therapeutic approaches to enhance patient outcomes and introduce innovative solutions. These advancements include new drug formulations and targeted therapies aimed at reducing polyp formation and slowing disease progression. For example, in June 2024, Biodexa Pharmaceuticals PLC, a UK-based biopharmaceutical company, shared promising results from its Phase 2 clinical trial of eRapa for FAP treatment. The trial demonstrated a 75% non-progression rate and a 17% median reduction in polyp burden over 12 months. In Cohort 2, participants experienced an even higher 81% non-progression rate and a 29% reduction in polyps with a specific dosing regimen. The treatment was well-tolerated, with a 95% compliance rate. These promising results pave the way for a Phase 3 trial involving approximately 168 high-risk FAP patients, potentially shifting treatment strategies from surgery to effective medical therapy.

Major players in the familial adenomatous polyposis treatment market are Mayo Clinic, Mount Sinai Health System, Johns Hopkins Medicine, Cleveland Clinic, UCLA Health, Houston Methodist Hospital, Scripps Health, Duke University Health System, Texas Children's Hospital, Massachusetts General Hospital, Inova Health Care Services, Brigham and Women's Hospital, Stanford Health Care, Barnes-Jewish Hospital, Northwestern Medicine, Geisinger Health, Max Healthcare, Sapience Therapeutics Inc., Frederick Gastroenterology Associates PA, Therapyx.

North America was the largest region in the familial adenomatous polyposis (FAP) treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial adenomatous polyposis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the familial adenomatous polyposis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial adenomatous polyposis treatment market consists of sales of non-steroidal anti-inflammatory drugs, chemo preventive agents and targeted therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Familial Adenomatous Polyposis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on familial adenomatous polyposis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for familial adenomatous polyposis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The familial adenomatous polyposis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Familial Adenomatous Polyposis Treatment Market Characteristics

3. Familial Adenomatous Polyposis Treatment Market Trends And Strategies

4. Familial Adenomatous Polyposis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Familial Adenomatous Polyposis Treatment Growth Analysis And Strategic Analysis Framework

6. Familial Adenomatous Polyposis Treatment Market Segmentation

7. Familial Adenomatous Polyposis Treatment Market Regional And Country Analysis

8. Asia-Pacific Familial Adenomatous Polyposis Treatment Market

9. China Familial Adenomatous Polyposis Treatment Market

10. India Familial Adenomatous Polyposis Treatment Market

11. Japan Familial Adenomatous Polyposis Treatment Market

12. Australia Familial Adenomatous Polyposis Treatment Market

13. Indonesia Familial Adenomatous Polyposis Treatment Market

14. South Korea Familial Adenomatous Polyposis Treatment Market

15. Western Europe Familial Adenomatous Polyposis Treatment Market

16. UK Familial Adenomatous Polyposis Treatment Market

17. Germany Familial Adenomatous Polyposis Treatment Market

18. France Familial Adenomatous Polyposis Treatment Market

19. Italy Familial Adenomatous Polyposis Treatment Market

20. Spain Familial Adenomatous Polyposis Treatment Market

21. Eastern Europe Familial Adenomatous Polyposis Treatment Market

22. Russia Familial Adenomatous Polyposis Treatment Market

23. North America Familial Adenomatous Polyposis Treatment Market

24. USA Familial Adenomatous Polyposis Treatment Market

25. Canada Familial Adenomatous Polyposis Treatment Market

26. South America Familial Adenomatous Polyposis Treatment Market

27. Brazil Familial Adenomatous Polyposis Treatment Market

28. Middle East Familial Adenomatous Polyposis Treatment Market

29. Africa Familial Adenomatous Polyposis Treatment Market

30. Familial Adenomatous Polyposis Treatment Market Competitive Landscape And Company Profiles

31. Familial Adenomatous Polyposis Treatment Market Other Major And Innovative Companies

32. Global Familial Adenomatous Polyposis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Familial Adenomatous Polyposis Treatment Market

34. Recent Developments In The Familial Adenomatous Polyposis Treatment Market

35. Familial Adenomatous Polyposis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기